Advantage Alpha Capital Partners LP Has $311,000 Stake in Xencor, Inc. (NASDAQ:XNCR)

Advantage Alpha Capital Partners LP reduced its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 45.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,548 shares of the biopharmaceutical company’s stock after selling 11,313 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Xencor were worth $311,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares during the period. KBC Group NV increased its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares during the last quarter. Quarry LP lifted its position in shares of Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 2,108 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,337 shares during the period. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Xencor during the 3rd quarter worth approximately $205,000.

Wall Street Analyst Weigh In

XNCR has been the topic of several research reports. Wells Fargo & Company decreased their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $12.95 on Tuesday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12-month low of $12.54 and a 12-month high of $27.24. The company’s 50 day moving average price is $16.22 and its two-hundred day moving average price is $20.30. The firm has a market cap of $912.48 million, a PE ratio of -4.05 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Equities research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.